Related Experiment Video
Updated: Sep 16, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation for Stroke Prevention in Patients with Atrial Fibrillation: A Review of the Literature and Current
Vrinda Vyas1, Vandita Vyas2, Akash Sharma3
1Cardiology, ECU Health, Tarboro, NC 27886, USA.
Insights
Direct oral anticoagulants and left atrial appendage occlusion devices are effective stroke prevention strategies for atrial fibrillation (AF) patients. These advancements offer safer alternatives to traditional treatments, improving outcomes and reducing healthcare costs.
Area of Science:
- Cardiology
- Internal Medicine
- Pharmacology
Background:
- Atrial fibrillation (AF) is the most common heart arrhythmia globally.
- AF increases stroke risk, mortality, and healthcare costs due to ineffective atrial contraction and thrombi formation.
- Stroke prevention is a critical management goal for AF patients.
Purpose of the Study:
- To review current recommendations for stroke prevention in AF.
- To provide an overview of literature on stroke prevention strategies in AF.
- To focus on direct-acting oral anticoagulants (DOACs) and non-pharmacological methods.
Main Methods:
- Literature review of current guidelines and studies on AF stroke prevention.
- Focus on direct-acting oral anticoagulants (DOACs) and left atrial appendage occlusion (LAAO) devices.
- Comparison of DOACs with traditional anticoagulants and discussion of LAAO benefits.
Main Results:
- DOACs are safer and more effective than warfarin for non-valvular AF stroke prevention.
- LAAO devices offer an alternative to lifelong anticoagulation for high-bleeding-risk patients.
- Current strategies have significantly evolved from aspirin and warfarin.
Conclusions:
- DOACs are now the preferred anticoagulant therapy for most non-valvular AF patients.
- LAAO devices provide a valuable non-pharmacological option for select AF patients.
- Continued research and adherence to guidelines are essential for optimal stroke prevention in AF.
Abstract:
Atrial fibrillation (AF) is the most common arrhythmia worldwide, characterized by uncoordinated atrial activation leading to a loss of effective atrial contraction and increased risk for atrial thrombi formation, promoting an increased risk of cardioembolic strokes and mortality, and associated increased healthcare expenditure. Therefore, stroke prevention represents a key focus in managing patients with atrial fibrillation, and strategies to achieve this aim have drastically evolved over the years. Previously, aspirin and warfarin were the cornerstone of stroke prophylaxis. However, direct oral anticoagulants have emerged and are now recognized as a safer and more effective alternative for non-valvular AF. Meanwhile, newer non-pharmacological methods to prevent AF related strokes, such as left atrial appendage occlusion devices, have been approved to ameliorate the need for lifelong anticoagulation in patients with elevated bleeding risks. This review outlines the current recommendations and provides an overview of the literature on stroke prevention in patients with atrial fibrillation, particularly focusing on using direct-acting oral anticoagulants. Comparisons between these agents and special considerations for use are also reviewed.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis IV: Nursing Management
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care